시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 PARP(Poly ADP-ribose Polymerase) 억제제 시장 보고서(2025년)
Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025
상품코드 : 1730994
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,516,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,419,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,322,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 PARP(Poly ADP-ribose Polymerase) 억제제 시장 규모는 향후 수년간 급성장이 예상됩니다. 예측기간의 성장은 의약품 생산 및 공급 증가, BRCA 돌연변이 암 유병률 상승, 유방암 이환율 증가, 단일클론항체의 사용 확대, 헬스케어 지출 증가 등의 요인에 의한 것으로 예측됩니다.

유방암의 유병률 증가는 PARP 억제제 시장의 성장을 가속할 것으로 예측됩니다. 유병률 상승의 요인으로는 인구의 고령화, 라이프 스타일의 변화, 유전적 요인, 호르몬 균형의 혼란, 비만, 음주, 환경 리스크에의 노출 등을 들 수 있습니다. PARP 억제제는 PARP 효소가 암세포 DNA 손상을 복구하는 능력을 저해함으로써 유방암 환자를 돕고, 특히 BRCA1 또는 BRCA2 돌연변이를 가진 종양에서 세포사멸을 일으킵니다.

PARP 억제제 시장의 기업은 일부 암에서 발견되는 특정 유전자 변이를 표적으로 한 항암제 등의 암 치료의 진전에 주력하고 있습니다. 예를 들면, 2024년 3월, 인도의 제약회사 Zydus Lifesciences Limited는 PARP 억제제 오라파리브의 제네릭 의약품인 IBYRA를 발매했습니다. 이 의약품은 HRD 양성과 BRCA 양성의 암 환자에게, 적당한 가격으로 적을 좁힌 치료 선택지를 제공해, 선발 의약품에 비해 치료비를 대폭 삭감합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

PARP inhibitors (poly(ADP-ribose) polymerase inhibitors) are a class of drugs primarily used in cancer treatment. These medications work by inhibiting DNA repair in cancer cells, especially in cancers with BRCA mutations. They are commonly prescribed for ovarian and breast cancers and are typically taken orally. PARP inhibitors help lower the risk of cancer recurrence after chemotherapy, though they may cause side effects such as fatigue and low blood cell counts.

The main types of PARP inhibitors include olaparib, rucaparib, niraparib, talazoparib, and others. Olaparib is a well-known PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers by blocking DNA repair in cancer cells, which leads to cell death. These drugs are used for various indications, including ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer. They are distributed via hospital pharmacies, retail pharmacies, and online platforms, and are utilized by hospitals, specialty clinics, research institutions, and other healthcare settings.

The poly (ADP-Ribose) polymerase (PARP) inhibitors market research report is one of a series of new reports from The Business Research Company that provides poly (ADP-Ribose) polymerase (PARP) inhibitors market statistics, including the poly (ADP-Ribose) polymerase (PARP) inhibitors industry global market size, regional shares, competitors with the poly (ADP-Ribose) polymerase (PARP) inhibitors market share, detailed poly (ADP-Ribose) polymerase (PARP) inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the poly (ADP-Ribose) polymerase (PARP) inhibitors industry. This poly (ADP-Ribose) polymerase (PARP) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The poly(ADP-ribose) polymerase (PARP) inhibitors market size has grown rapidly in recent years. It will grow from $6.53 billion in 2024 to $7.56 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth during the historic period can be attributed to factors such as the rising incidence of cancer, increased genetic testing, higher success rates in clinical trials, expanding insurance coverage, and growth in cancer research.

The poly(ADP-ribose) polymerase (PARP) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $13.45 billion in 2029 at a compound annual growth rate (CAGR) of 15.5%. The growth during the forecast period can be attributed to factors such as the increasing production and supply of drugs, the rising prevalence of BRCA-mutated cancers, the growing incidence of breast cancer, the expanding use of monoclonal antibodies, and rising healthcare expenditure. Key trends in the forecast period include advancements in biomarker research, the use of combination therapies, the integration of artificial intelligence in drug development, progress in biomarker-driven therapies, and the development of next-generation PARP inhibitors.

The increasing prevalence of breast cancer is expected to drive the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market. Breast cancer is a disease where breast cells grow uncontrollably, forming malignant tumors that can spread to other areas of the body. Factors contributing to the rising prevalence include aging populations, lifestyle changes, genetic factors, hormonal imbalances, obesity, alcohol consumption, and exposure to environmental risks. PARP inhibitors help breast cancer patients by blocking the PARP enzyme's ability to repair DNA damage in cancer cells, causing cell death, particularly in tumors with BRCA1 or BRCA2 mutations. According to the National Breast Cancer Foundation, in January 2025, one in eight women in the United States will be diagnosed with breast cancer in their lifetime. In 2024, 310,720 women and 2,800 men were diagnosed with invasive breast cancer. As a result, the increasing prevalence of breast cancer is fueling the growth of the PARP inhibitors market.

Companies in the PARP inhibitors market are focused on advancing cancer treatments, such as anticancer medications, to target specific genetic mutations found in some cancers. These medicines work by inhibiting the growth of cancer cells, preventing their spread, or destroying them through various mechanisms, such as interfering with cell division, blocking proteins necessary for tumor growth, or stimulating the immune system to combat cancer. For instance, in March 2024, Zydus Lifesciences Limited, a pharmaceutical company based in India, launched IBYRA, a generic version of the PARP inhibitor olaparib. This drug offers an affordable and targeted treatment option for patients with HRD-positive and BRCA-positive cancers, significantly reducing treatment costs compared to the original medication.

In June 2023, Ariceum Therapeutics GmbH, a biotechnology company based in Germany, acquired Theragnostics Ltd. for an undisclosed amount. This acquisition aims to expand Ariceum Therapeutics' radiopharmaceutical pipeline by incorporating Theragnostics' next-generation PARP inhibitor radiation therapies, while also strengthening its U.S. operations. Theragnostics Ltd, a U.K.-based biopharmaceutical company, specializes in developing radio-labeled PARP inhibitors.

Major players in the poly(ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., and Allarity Therapeutics Inc.

North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in poly(ADP-ribose) polymerase (PARP) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The poly(ADP-ribose) polymerase (PARP) inhibitors market consists of sales of rubraca, zejula, and talzenna. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on poly(adp-ribose) polymerase (parp) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for poly(adp-ribose) polymerase (parp) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The poly(adp-ribose) polymerase (parp) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Characteristics

3. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Trends And Strategies

4. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Growth Analysis And Strategic Analysis Framework

6. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Segmentation

7. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Regional And Country Analysis

8. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

9. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

10. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

11. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

12. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

13. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

14. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

15. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

16. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

17. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

18. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

19. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

20. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

21. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

22. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

23. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

24. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

25. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

26. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

27. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

28. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

29. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

30. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Landscape And Company Profiles

31. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Other Major And Innovative Companies

32. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

34. Recent Developments In The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

35. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기